See more : Showa Chemical Industry Co., Ltd. (4990.T) Income Statement Analysis – Financial Results
Complete financial analysis of Alnylam Pharmaceuticals, Inc. (ALNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alnylam Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Eastern Platinum Limited (ELR.TO) Income Statement Analysis – Financial Results
- Friedrich Vorwerk Group SE (VH2.DE) Income Statement Analysis – Financial Results
- Feng Tay Enterprises Co., Ltd. (9910.TW) Income Statement Analysis – Financial Results
- Canopy Growth Corporation (CGC) Income Statement Analysis – Financial Results
- SouthGobi Resources Ltd. (SGQ.TO) Income Statement Analysis – Financial Results
Alnylam Pharmaceuticals, Inc. (ALNY)
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.83B | 1.04B | 844.29M | 492.85M | 219.75M | 74.91M | 89.91M | 47.16M | 41.10M | 50.56M | 47.17M | 66.73M | 82.76M | 100.04M | 100.53M | 96.16M | 50.90M | 26.93M | 5.72M | 4.28M | 176.00K | 0.00 |
| Cost of Revenue | 310.41M | 168.82M | 140.14M | 78.05M | 25.06M | 1.80M | 13.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.52B | 868.60M | 704.14M | 414.80M | 194.69M | 73.11M | 76.55M | 47.16M | 41.10M | 50.56M | 47.17M | 66.73M | 82.76M | 100.04M | 100.53M | 96.16M | 50.90M | 26.93M | 5.72M | 4.28M | 176.00K | 0.00 |
| Gross Profit Ratio | 83.02% | 83.73% | 83.40% | 84.16% | 88.60% | 97.59% | 85.13% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 1.00B | 883.02M | 792.16M | 654.82M | 655.11M | 505.42M | 390.64M | 382.39M | 276.50M | 190.25M | 112.96M | 86.57M | 99.30M | 106.38M | 108.73M | 96.88M | 120.69M | 49.80M | 35.32M | 24.60M | 13.10M | 3.34M |
| General & Administrative | 795.65M | 770.66M | 620.64M | 588.42M | 479.01M | 382.36M | 199.37M | 89.35M | 60.61M | 44.53M | 27.15M | 44.61M | 38.28M | 37.73M | 39.91M | 27.12M | 23.39M | 16.63M | 13.87M | 11.94M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 795.65M | 770.66M | 620.64M | 588.42M | 479.01M | 382.36M | 199.37M | 89.35M | 60.61M | 44.53M | 27.15M | 44.61M | 38.28M | 37.73M | 39.91M | 27.12M | 23.39M | 16.63M | 13.87M | 11.94M | 7.53M | 880.00K |
| Other Expenses | 0.00 | -109.37M | -2.05M | 45.53M | 20.73M | 4.17M | -3.02M | 6.17M | 76.00K | 1.82M | -47.00K | 331.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.80B | 1.65B | 1.41B | 1.24B | 1.13B | 887.78M | 590.00M | 471.75M | 337.11M | 234.78M | 140.11M | 131.18M | 137.58M | 144.11M | 148.64M | 124.00M | 144.07M | 66.43M | 49.19M | 36.54M | 20.62M | 4.22M |
| Cost & Expenses | 2.11B | 1.82B | 1.55B | 1.32B | 1.16B | 889.58M | 590.00M | 471.75M | 337.11M | 234.78M | 140.11M | 131.18M | 137.58M | 144.11M | 148.64M | 124.00M | 144.07M | 66.43M | 49.19M | 36.54M | 20.62M | 4.22M |
| Interest Income | 95.56M | 24.81M | 1.58M | 11.81M | 33.45M | 29.26M | 12.24M | 8.31M | 5.86M | 2.56M | 1.07M | 977.00K | 1.21M | 2.31M | 5.39M | 14.41M | 15.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 121.22M | 155.97M | 143.02M | 84.50M | 0.00 | 29.26M | 12.24M | 8.31M | 5.86M | 2.56M | 1.07M | 977.00K | 1.21M | 2.31M | 5.39M | 872.00K | 1.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 54.05M | 44.47M | 47.57M | 34.77M | 17.18M | 6.44M | 13.37M | 15.13M | 19.05M | 11.93M | 10.23M | 9.04M | 5.13M | 4.94M | 5.99M | 5.73M | 4.08M | 3.82M | 3.12M | 2.44M | 838.00K | 36.00K |
| EBITDA | -258.24M | -926.56M | -661.56M | -736.33M | -868.08M | -754.24M | -488.19M | -409.46M | -276.96M | -172.29M | -82.71M | -51.71M | -49.69M | -38.06M | -41.02M | -18.93M | -75.06M | -35.69M | -38.83M | -29.55M | -19.61M | -4.19M |
| EBITDA Ratio | -14.12% | -86.22% | -83.99% | -156.46% | -427.50% | -1,115.02% | -556.20% | -900.33% | -720.27% | 72.29% | -197.05% | -23.29% | -65.60% | -50.45% | -47.38% | -23.62% | -174.50% | -131.57% | -705.58% | -691.61% | -8,507.39% | 0.00% |
| Operating Income | -282.18M | -785.07M | -708.65M | -828.44M | -939.43M | -814.67M | -500.09M | -424.59M | -296.01M | -404.98M | -92.94M | -129.46M | -54.82M | -44.07M | -48.11M | -27.84M | -93.18M | -39.50M | -43.47M | -32.26M | -25.06M | -4.22M |
| Operating Income Ratio | -15.43% | -75.68% | -83.93% | -168.09% | -427.50% | -1,087.56% | -556.20% | -900.33% | -720.27% | -800.97% | -197.05% | -194.01% | -66.24% | -44.05% | -47.86% | -28.95% | -183.07% | -146.68% | -760.53% | -754.18% | -14,236.93% | 0.00% |
| Total Other Income/Expenses | -151.34M | -341.92M | -143.49M | -27.16M | 54.18M | 54.00M | 9.21M | 14.48M | 5.94M | 4.38M | 1.02M | 12.87M | -2.83M | 1.07M | 1.10M | 2.31M | 12.96M | 4.89M | 558.00K | -390.00K | -4.64M | 0.00 |
| Income Before Tax | -433.52M | -1.13B | -852.14M | -855.60M | -885.25M | -760.67M | -490.87M | -410.11M | -290.07M | -400.60M | -91.92M | -116.59M | -57.65M | -43.00M | -47.01M | -25.53M | -80.22M | -34.61M | -42.91M | -35.37M | -29.69M | 0.00 |
| Income Before Tax Ratio | -23.71% | -108.63% | -100.93% | -173.60% | -402.85% | -1,015.48% | -545.95% | -869.63% | -705.83% | -792.32% | -194.88% | -174.73% | -69.66% | -42.98% | -46.76% | -26.55% | -157.61% | -128.51% | -750.77% | -826.72% | -16,871.59% | 0.00% |
| Income Tax Expense | 6.73M | 4.16M | 680.00K | 2.68M | 863.00K | 823.00K | -25.60M | -23.44M | -24.91M | -40.21M | -2.70M | -10.57M | -5.80M | 514.00K | 582.00K | 719.00K | 5.25M | -4.89M | -558.00K | 390.00K | 4.59M | -86.00K |
| Net Income | -440.24M | -1.13B | -852.82M | -858.28M | -886.12M | -761.50M | -490.87M | -410.11M | -290.07M | -360.40M | -89.23M | -106.01M | -57.65M | -43.52M | -47.59M | -26.25M | -85.47M | -34.61M | -42.91M | -32.65M | -25.03M | -4.14M |
| Net Income Ratio | -24.08% | -109.04% | -101.01% | -174.15% | -403.24% | -1,016.58% | -545.95% | -869.63% | -705.83% | -712.79% | -189.17% | -158.88% | -69.66% | -43.50% | -47.34% | -27.30% | -167.92% | -128.51% | -750.77% | -763.30% | -14,223.30% | 0.00% |
| EPS | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 | -4.85 | -1.45 | -2.11 | -1.36 | -1.04 | -1.14 | -0.64 | -2.21 | -1.09 | -1.96 | -2.75 | -26.56 | -12.48 |
| EPS Diluted | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 | -4.85 | -1.45 | -2.11 | -1.36 | -1.04 | -1.14 | -0.64 | -2.21 | -1.09 | -1.96 | -2.75 | -26.56 | -12.48 |
| Weighted Avg Shares Out | 124.91M | 121.69M | 118.45M | 114.99M | 109.26M | 100.59M | 90.55M | 85.60M | 83.99M | 74.28M | 61.55M | 50.29M | 42.41M | 42.04M | 41.63M | 41.08M | 38.66M | 31.89M | 21.95M | 11.89M | 942.67K | 331.34K |
| Weighted Avg Shares Out (Dil) | 124.91M | 121.69M | 118.45M | 114.99M | 109.26M | 100.59M | 90.55M | 85.60M | 83.99M | 74.28M | 61.55M | 50.29M | 42.41M | 42.04M | 41.63M | 41.08M | 38.66M | 31.89M | 21.95M | 11.89M | 942.67K | 331.34K |
Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALNY
Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick
Did Alnylam Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ALNY
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
Levi & Korsinsky Announces an Investigation on Behalf of Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who May Have Been Affected by Fraud
Investors who lost money on Alnylam Pharmaceuticals, Inc. should contact Levi & Korsinsky about an ongoing investigation - ALNY
Alnylam Being Investigated on Behalf of Alnylam Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.
Lost Money on Alnylam Pharmaceuticals, Inc.(ALNY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Alnylam Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ALNY
Did Alnylam Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- ALNY
Source: https://incomestatements.info
Category: Stock Reports